Loading
A phase 3 trial testing PF-07248144 in HR-positive / HER2-negative breast cancer, now recruiting.
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment is a phase 3 interventional study registered as NCT07062965, led by Pfizer, and recruiting on the registry. Official title: An Interventional, Open-Label, Randomised, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy. Planned enrolment is 400 participants (estimated). The study started in 2025-08-05 and primary completion is expected in 2027-07-22. No results have been posted on ClinicalTrials.gov.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, Pfizer (incl. Seagen), HR-positive / HER2-negative breast cancer.
Shares Pfizer (incl. Seagen), HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares PF-07248144, Pfizer (incl. Seagen).
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.